(Q82715862)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21127470%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

title

Renal protective effects of aliskiren beyond its antihypertensive property in a mouse model of progressive fibrosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21127470%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21127470%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Oliver Gross

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21127470%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Diana Rubel

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21127470%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Johanna Temme

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21127470%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Stephanie Theissen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21127470%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Gerhard-Anton Müller

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21127470%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

2 December 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21127470%20AND%20SRC:MED&resulttype=core&format=json

Journal of Clinical Hypertension

17 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21127470%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21127470%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21127470%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

355-361

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21127470%20AND%20SRC:MED&resulttype=core&format=json

Chronic kidney disease predicts cardiovascular disease

17 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.231

7 January 2021

Tubulointerstitial changes as a major determinant in the progression of renal damage

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.231

7 January 2021

Cellular and molecular pathways that lead to progression and regression of renal fibrogenesis.

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.231

7 January 2021

Renal fibrosis: an update

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.231

7 January 2021

Pathways to nephron loss starting from glomerular diseases-insights from animal models

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.231

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.231

7 January 2021

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.231

7 January 2021

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.231

7 January 2021

Aliskiren: a novel renoprotective agent or simply an alternative to ACE inhibitors?

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.231

7 January 2021

Aliskiren combined with losartan in type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.231

7 January 2021

The putative (pro)renin receptor blocker HRP fails to prevent (pro)renin signaling

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.231

7 January 2021

A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR)

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.231

7 January 2021

Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.231

7 January 2021

Collagen COL4A3 knockout: a mouse model for autosomal Alport syndrome

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.231

7 January 2021

Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.231

7 January 2021

Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.231

7 January 2021

Renoprotection: clues from knockout models of rare diseases

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.231

7 January 2021

Nephroprotection by antifibrotic and anti-inflammatory effects of the vasopeptidase inhibitor AVE7688

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.231

7 January 2021

HEREDITARY FAMILIAL CONGENITAL HAEMORRHAGIC NEPHRITIS.

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.231

7 January 2021

Therapeutic benefit of captopril in salt-loaded stroke-prone spontaneously hypertensive rats is independent of hypotensive effect

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.231

7 January 2021

Angiotensin II and renal fibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.231

7 January 2021

Interstitial inflammation in Alport syndrome

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.231

7 January 2021

Monocytes may promote myofibroblast accumulation and apoptosis in Alport renal fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.231

7 January 2021

Integrin alpha1beta1 and transforming growth factor-beta1 play distinct roles in alport glomerular pathogenesis and serve as dual targets for metabolic therapy

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.231

7 January 2021

Aldosterone, but not angiotensin II, increases profibrotic factors in kidney of adrenalectomized stroke-prone spontaneously hypertensive rats

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.231

7 January 2021

The effect of aldosterone blockade in patients with Alport syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.231

7 January 2021

Activation of a local renin angiotensin system in podocytes by glucose

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.231

7 January 2021

Bone marrow-derived cells contribute to podocyte regeneration and amelioration of renal disease in a mouse model of Alport syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.231

7 January 2021

Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.231

7 January 2021

Role for transforming growth factor-beta1 in alport renal disease progression.

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.231

7 January 2021

Identifiers

DOI

10.1038/AJH.2010.231

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21127470%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference